BIO and Virginia BIO Praise 21st Century Cures Act House Approval
Monday, July 20, 2015
On July 10, 2015, the U.S. House of Representatives overwhelmingly approved the 21st Century Cures Act by a bipartisan vote of 344-77. The 21st Century Cures Act is designed to ensure the laws, regulations, and resources keep pace with scientific advances while maintaining the gold-standard level of safety for patients.
The idea conceived a year and a half ago that Congress could work together to help boost research and innovation by listening to patients, researchers, innovators, and health experts from across the health spectrum and across the country took a vital first step with this House passage. It currently takes 10 years for new life-saving drugs and devices to navigate through the approval process.
After the passage, President and CEO of BIO, Jim Greenwood, stated “We praise the House of Representatives for today’s vote to pass 21st Century Cures legislation that recognizes the critical link between research, development and reimbursement to expedite the delivery of breakthrough treatments and cures to patients suffering from life-threatening and debilitating diseases.”
He continued, “This bill represents forward-looking public policies that sustain scientific discovery and promote biomedical advancement. The future of medicine will harness 21st century scientific tools, advancements in molecular biology, and novel bioinformatics to develop and improve upon therapies that can prevent, diagnose, and treat all stages of disease. This landmark legislation would lay the groundwork for transforming patient care by encouraging innovative approaches to drug discovery, development and delivery.
We also embrace the focus on precision medicine through genomics and regulatory science. Industrial scale biomarker qualification and full genome sequencing will help us better understand the molecular basis of disease and develop precision therapies tailored to each patient.”